A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance
Abstract Disk-like domain receptor 1 (DDR1) is a crucial regulator of pro-inflammatory mediators and matrix-degrading enzymes. Although mounting evidence supports a vital role for DDR1 in the tumorigenesis of some cancers, no pan-cancer analysis of DDR1 has been reported. Therefore, we aimed to expl...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-27975-9 |
| _version_ | 1797850062521368576 |
|---|---|
| author | Longfei Yang Yuwei Zhang Yifan Tang Yang Wang Peng Jiang Fengping Liu Ninghan Feng |
| author_facet | Longfei Yang Yuwei Zhang Yifan Tang Yang Wang Peng Jiang Fengping Liu Ninghan Feng |
| author_sort | Longfei Yang |
| collection | DOAJ |
| description | Abstract Disk-like domain receptor 1 (DDR1) is a crucial regulator of pro-inflammatory mediators and matrix-degrading enzymes. Although mounting evidence supports a vital role for DDR1 in the tumorigenesis of some cancers, no pan-cancer analysis of DDR1 has been reported. Therefore, we aimed to explore the prognostic value of DDR1 in 33 cancer types and investigate its potential immune function. We used a range of bioinformatics approaches to explore the potential carcinogenic role of DDR1 in multiple cancers. We found that DDR1 was expressed at high levels in most cancers. DDR1 expression was positively or negatively associated with prognosis in different cancers. DDR1 expression was significantly associated with DNA methylation in 8 cancers, while there was a correlation between DDR1 expression and RNA methylation-related genes and mismatch repair gene in most cancers. Furthermore, DDR1 expression was significantly associated with microsatellite instability in 6 cancers and tumor mutation burden in 11 cancers. In addition, DDR1 expression was also significantly correlated with immune cell infiltration, tumor microenvironment, immune-related genes, and drug resistance in various cancers. In conclusion, DDR1 can serve as a potential therapeutic target and prognostic marker for various malignancies due to its vital role in tumorigenesis and tumor immunity. |
| first_indexed | 2024-04-09T18:55:24Z |
| format | Article |
| id | doaj.art-db57663c4b944b8e891a07f0a9b07722 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-09T18:55:24Z |
| publishDate | 2023-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-db57663c4b944b8e891a07f0a9b077222023-04-09T11:16:05ZengNature PortfolioScientific Reports2045-23222023-04-0113111710.1038/s41598-023-27975-9A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistanceLongfei Yang0Yuwei Zhang1Yifan Tang2Yang Wang3Peng Jiang4Fengping Liu5Ninghan Feng6Medical School of Nantong UniversityMedical School of Nantong UniversityDepartment of Urology, Affiliated Wuxi No. 2 Hospital of Nanjing Medical UniversityDepartment of Urology, Affiliated Wuxi No. 2 Hospital of Nanjing Medical UniversityDepartment of Urology, Affiliated Wuxi No. 2 Hospital of Nanjing Medical UniversityWuxi School of Medicine, Jiangnan UniversityMedical School of Nantong UniversityAbstract Disk-like domain receptor 1 (DDR1) is a crucial regulator of pro-inflammatory mediators and matrix-degrading enzymes. Although mounting evidence supports a vital role for DDR1 in the tumorigenesis of some cancers, no pan-cancer analysis of DDR1 has been reported. Therefore, we aimed to explore the prognostic value of DDR1 in 33 cancer types and investigate its potential immune function. We used a range of bioinformatics approaches to explore the potential carcinogenic role of DDR1 in multiple cancers. We found that DDR1 was expressed at high levels in most cancers. DDR1 expression was positively or negatively associated with prognosis in different cancers. DDR1 expression was significantly associated with DNA methylation in 8 cancers, while there was a correlation between DDR1 expression and RNA methylation-related genes and mismatch repair gene in most cancers. Furthermore, DDR1 expression was significantly associated with microsatellite instability in 6 cancers and tumor mutation burden in 11 cancers. In addition, DDR1 expression was also significantly correlated with immune cell infiltration, tumor microenvironment, immune-related genes, and drug resistance in various cancers. In conclusion, DDR1 can serve as a potential therapeutic target and prognostic marker for various malignancies due to its vital role in tumorigenesis and tumor immunity.https://doi.org/10.1038/s41598-023-27975-9 |
| spellingShingle | Longfei Yang Yuwei Zhang Yifan Tang Yang Wang Peng Jiang Fengping Liu Ninghan Feng A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance Scientific Reports |
| title | A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance |
| title_full | A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance |
| title_fullStr | A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance |
| title_full_unstemmed | A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance |
| title_short | A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance |
| title_sort | pan cancer analysis of ddr1 in prognostic signature and tumor immunity drug resistance |
| url | https://doi.org/10.1038/s41598-023-27975-9 |
| work_keys_str_mv | AT longfeiyang apancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT yuweizhang apancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT yifantang apancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT yangwang apancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT pengjiang apancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT fengpingliu apancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT ninghanfeng apancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT longfeiyang pancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT yuweizhang pancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT yifantang pancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT yangwang pancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT pengjiang pancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT fengpingliu pancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance AT ninghanfeng pancanceranalysisofddr1inprognosticsignatureandtumorimmunitydrugresistance |